thymosin alpha-1 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-08. Numbers and descriptions here follow the published literature rather than marketing material.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
=== Semiconductors === In 2014, researchers proved that they can create electrically conductive thin films of MOFs (Cu3(btc)2 (also known as HKUST-1; BTC, benzene-1,3,5-tricarboxylic acid) infiltrated with the molecule 7,7,8,8-tetracyanoquinododimethane) that could be used in applications including photovoltaics, sensors, and electronic materials and a path toward creating semiconductors. The team demonstrated tunable, air-stable electrical conductivity with values as high as 7 siemens per meter, comparable to bronze. Ni3(2,3,6,7,10,11-hexaiminotriphenylene)2 was shown to be a metal-organic graphene analogue that has a natural band gap, making it a semiconductor, and is able to self-assemble. It is an example of conductive metal-organic framework. It represents a family of similar compounds. Because of the symmetry and geometry in 2,3,6,7,10,11-hexaiminotriphenylene (hitp), the overall organometallic complex has an almost fractal nature that allows it to perfectly self-organize. By contrast, graphene must be doped to give it the properties of a semiconductor. Ni3(hitp)2 pellets had a conductivity of 2 S/cm, a record for a metal-organic compound. In 2018, researchers synthesized a two-dimensional semiconducting MOF (Fe3(THT)2(NH4)3, also known as THT, 2,3,6,7,10,11-triphenylenehexathiol) and showed high electric mobility at room temperature. In 2020 the same material was integrated in a photo-detecting device, detecting a broad wavelength range from UV to NIR (400–1575 nm).
== Methodology == Using the PDCAAS method, the protein quality rankings are determined by comparing the amino acid profile of the specific food protein against a standard amino acid profile with the highest possible score being a 1.0. This score means, after digestion of the protein, it provides per unit of protein 100% or more of the indispensable amino acids required. The formula for calculating the PDCAAS percentage is: FTPD × AAS × 100%, where FTPD is fecal true digestibility and AAS is the amino acid score.
=== Chromatography === Internal standards are used in GC/MS and LC/MS to control for variability introduced by injection, sample preparation and other matrix effects. The ratio of peak areas between the internal standard and analyte is calculated to determine analyte concentration. A common type of internal standard is an isotopically labeled analogue of the analyte, which incorporates one or more atoms of 2H, 13C, 15N and 18O into its structure.
Sources: en.wikipedia.org
The Nelson brothers, butchers in County Meath, Ireland, started shipping extensive live beef shipments to Liverpool, England. They successfully expanded their beef business until their imports from Ireland were insufficient to supply their rapidly growing business and Nelson decided to investigate the possibility of importing meat from Argentina. The first refrigerated ship they bought was Spindrift which they renamed in 1890 SS Highland Scot. A vessel of 3,060 gross tons bought by James Nelson and Sons in 1889 and fitted with a somewhat primitive refrigerating plant operating on the cold air system became one of the pioneer vessels in the trade of refrigerated meat and other perishable commodities. They hauled beef carcasses from Argentina to Britain. Their regularly scheduled shipments and ships developed into the Nelson Line that was formed in 1880 for the meat trade from Argentina to UK. Refrigeration made it possible to import meat from the United States, New Zealand, Argentina and Australia.
There are three major regions that center around drug trafficking, known as the Golden Triangle (Burma, Laos, Thailand), Golden Crescent (Afghanistan) and Central and South America. There are suggestions that due to the continuing decline in opium production in South East Asia, traffickers may begin to look to Afghanistan as a source of heroin." With respect to organized crime and accelerating synthetic drug production in East and Southeast Asia, especially the Golden Triangle, Sam Gor, also known as The Company, is the most prominent international crime syndicate based in Asia-Pacific. It is made up of members of five different triads. Sam Gor is understood to be headed by Chinese-Canadian Tse Chi Lop. The Cantonese Chinese syndicate is primarily involved in drug trafficking, earning at least $8 billion per year. Sam Gor is alleged to control 40% of the Asia-Pacific methamphetamine market, while also trafficking heroin and ketamine. The organization is active in a variety of countries, including Myanmar, Thailand, New Zealand, Australia, Japan, China and Taiwan. Sam Gor previously produced meth in Southern China and is now believed to manufacture mainly in the Golden Triangle, specifically Shan State, Myanmar, responsible for much of the massive surge of crystal meth in recent years. The group is understood to be headed by Tse Chi Lop, a Chinese-Canadian gangster born in Guangzhou, China. Tse is a former member of the Hong Kong-based crime group, the Big Circle Gang. In 1988, Tse immigrated to Canada.
J. Charles Jennette is a physician, nephropathologist, academic, and author. He served as Kenneth M. Brinkhous Distinguished Professor and Chair of Pathology and Laboratory Medicine at the University of North Carolina at Chapel Hill School of Medicine, and Chief of Pathology and Laboratory Medicine Services at UNC Hospitals from 1999 to 2019. Jennette's research focuses on understanding the causes of kidney diseases, particularly those induced by inflammatory and immunologic mechanisms, and improving the diagnosis and treatment of these diseases. He has authored and edited books, book chapters and articles in medical journals, and is an editor of four editions of the nephropathology textbook titled Heptinstall's Pathology of the Kidney. He has more than 25 named lectureships including the UNC School of Medicine 2015 Norma Berryhill Distinguished Lecture. He is the recipient of the Order of the Long Leaf Pine Award from the Governor of North Carolina for exemplary service to the State, Distinguished Service Award of the Association of Pathology Chairs, UNC Medical Alumni Distinguished Faculty Award, and Robert H. Heptinstall Lifetime Achievement Award from the Renal Pathology Society. Jennette served as the founding Secretary Treasurer of the Renal Pathology Society from 1993 until 1998, was elected vice president in 2003, and became president in 2004. He also served as President of the Association of Pathology Chairs from 2008 until 2010.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.